HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Childhood celiac disease in Estonia: efficacy of the IgA-class antigliadin antibody test in the search for new cases.

Abstract
The incidence of celiac disease (CD) and the role of IgA-class antigliadin antibody (AGA) determination in revealing new CD cases were studied in Estonia. Altogether 36 cases of CD in Estonian children were diagnosed from January 1976 through June 1992 by criteria recommended by the European Society for Paediatric Gastroenterology and Nutrition. A significant increase was observed in the incidence of CD in Estonia (from 1:25, 130 live births during 1976-1989 to about 1:2,700 live births during 1990-1992), due mainly to the introduction of IgA-class AGA determinations in an active search for celiac patients since 1990. A total of 29 IgA-class AGA-positive cases was revealed among 1,048 children screened, and 23 of them had CD. Thus, the results show a relatively low incidence of CD in Estonia compared to the figures in neighboring countries. However, the incidence will probably increase if a larger pediatric population can be screened for CD using IgA-class AGA enzyme-linked immunosorbent assay.
AuthorsO Uibo
JournalJournal of pediatric gastroenterology and nutrition (J Pediatr Gastroenterol Nutr) Vol. 18 Issue 1 Pg. 53-5 (Jan 1994) ISSN: 0277-2116 [Print] United States
PMID8126618 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • Immunoglobulin A
  • Gliadin
Topics
  • Adolescent
  • Antibodies (blood)
  • Celiac Disease (diagnosis, epidemiology)
  • Child
  • Child, Preschool
  • Enzyme-Linked Immunosorbent Assay
  • Estonia
  • Female
  • Gliadin (immunology)
  • Humans
  • Immunoglobulin A (blood)
  • Infant
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: